High Response Rates to CAR-T Seen in Mantle Cell Lymphoma
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma.
Hematologic Cancer
HEMATOLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic. -
CAR-T in ALL: Records Reveal Direct Costs for Hospitalization Approach $300K
The median total cost of hospitalization resulting from CAR-T treatment was found to be $380,052, with a median direct cost of $262,981. -
Chronic Lymphocytic Leukemia Treatment Decision Making With Venetoclax-Based Therapy
A review of case studies that outline treatment decisions based on patient and disease characteristics. -
CAR-NK Cells Make Their Debut in Hematologic Cancers
The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.
HEMATOLOGIC CANCER NEWS
Persistent Leukocytosis as a Marker for Disease Progression in Polycythemia Vera
DLBCL-Type Richter Transformation Associated With Worse Prognosis vs DLBCL
Hairy Cell Leukemia: Cladribine With Concurrent Rituximab May Improve Outcomes
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Rationales for Selecting CD19-Targeted Therapy in R/R B-Cell ALL
Want to read more?
Please login or register first to view this content.
Next post in Hematologic Cancers
